( Cytos Biotechnology reports positive re...)Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy,Health

Cytos Biotechnology reports positive results from placebo controlled phase IIa study in patients suffering from house dust mite allergy

SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a multi-centre and placebo-controlled phase IIa study with different formulations of CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to house dust mite allergy and assessed in a double-blind setting the safety, tolerability and exploratory efficacy of CYT003-QbG10 monotherapy, CYT003-QbG10 combined with a low dose of house dust mite allergen extract (designated CYT005-AllQbG10), allergen extract alone and placebo. Exploratory efficacy was determined by evaluating the allergic disease status of the patients before and after treatment by the conjunctival provocation test.

Both formulations of CYT003-QbG10 tested were safe and well tolerated. The table below summarizes
on the first results obtained two weeks after the last dose. A statistically significant increase in the
median allergen tolerance against baseline was observed only in the two treatment arms which
comprised QbG10 (i.e. CYT003-QbG10 monotherapy and CYT005-AllQbG10), whereas none of the
intergroup comparisons achieved statistical significance.

CYT003-QbG10
n=10
CYT005-AllQbG10
n=10
Placebo
n=10
Allergen
n=10
Increase of median
allergen tolerance
against baseline
factor of 10
factor of 10
factor of 1
factor of 10
p-value <0.05 <0.05 n.s. n.s.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology commented: “With each study we gain a deeper
understanding of the activity of QbG10 in allergic diseases. If we look at the entire data set of the
80 allergic pa
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis